88 related articles for article (PubMed ID: 17211520)
21. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.
Magnusson MK; Meade KE; Nakamura R; Barrett J; Dunbar CE
Blood; 2002 Aug; 100(3):1088-91. PubMed ID: 12130532
[TBL] [Abstract][Full Text] [Related]
22. [Pharmazie in unserer Zeit 5/2008].
Dingermann T; Laufer S; Winckler T
Pharm Unserer Zeit; 2008; 37(5):349. PubMed ID: 18729281
[No Abstract] [Full Text] [Related]
23. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
24. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
25. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
26. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
Magnusson MK; Meade KE; Brown KE; Arthur DC; Krueger LA; Barrett AJ; Dunbar CE
Blood; 2001 Oct; 98(8):2518-25. PubMed ID: 11588050
[TBL] [Abstract][Full Text] [Related]
27. Hypereosinophilic syndrome: diagnosis and treatment.
Peros-Golubicić T; Smojver-Jezek S
Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloproliferative disorder with ETV6-PDGFRβ fusion gene.
Tipirneni E; Buttar A; Brettler D; Miron P; Bathini V
Ann Hematol; 2012 Apr; 91(4):637-8. PubMed ID: 21833478
[No Abstract] [Full Text] [Related]
29. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
30. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
[TBL] [Abstract][Full Text] [Related]
31. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
32. Current management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
[No Abstract] [Full Text] [Related]
33. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
Leipner C; Grün K; Müller A; Buchdunger E; Borsi L; Kosmehl H; Berndt A; Janik T; Uecker A; Kiehntopf M; Böhmer FD
Cardiovasc Res; 2008 Jul; 79(1):118-26. PubMed ID: 18326555
[TBL] [Abstract][Full Text] [Related]
34. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Nardi V; Raz T; Cao X; Wu CJ; Stone RM; Cortes J; Deininger MW; Church G; Zhu J; Daley GQ
Oncogene; 2008 Jan; 27(6):775-82. PubMed ID: 17684485
[TBL] [Abstract][Full Text] [Related]
35. [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery].
Jönsson S; Lewerin C; Jacobsson S; Wadenvik H
Lakartidningen; 2006 Sep 6-12; 103(36):2556-9. PubMed ID: 17007200
[No Abstract] [Full Text] [Related]
36. Imatinib mesylate for the treatment of chronic myeloid leukemia.
Soverini S; Martinelli G; Iacobucci I; Baccarani M
Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.
Dalal BI; Horsman DE; Bruyèrè H; Forrest DL
Am J Hematol; 2007 Jan; 82(1):77-9. PubMed ID: 17133421
[No Abstract] [Full Text] [Related]
38. Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis.
Patnaik MM; Lasho TL; Finke CM; Pardanani A; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E12-4. PubMed ID: 26662677
[No Abstract] [Full Text] [Related]
39. Eosinophilia: secondary, clonal and idiopathic.
Tefferi A; Patnaik MM; Pardanani A
Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
[TBL] [Abstract][Full Text] [Related]
40. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2).
Morerio C; Acquila M; Rosanda C; Rapella A; Dufour C; Locatelli F; Maserati E; Pasquali F; Panarello C
Cancer Res; 2004 Apr; 64(8):2649-51. PubMed ID: 15087372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
